Warning on risks: Financial contracts for difference are complex instruments and are associated with a high risk of rapid financial losses due to leverage. On 72.29% of retail investor accounts, financial losses occur when trading financial contracts for difference with this provider. You should consider whether you understand how financial contracts for difference work, and whether you can afford to take the high risk of suffering financial losses. Please read the Risk Disclosures.

Market analysis and news

Get an overview of current market developments with regular analysis from our analysts. We offer a detailed view of key events, economic indicators and investment opportunities. Follow the development of the markets with us and make decisions based on data and experience.

1/1/2024

Expectations from Tesla's Cybertrack

Tesla Inc ( TSLA ) has been in the spotlight with its long-awaited Cybertruck model not only because of its innovative design, but also because of delays and a high price tag. Analysts are now expressing concern that Cybertruck's impact on Tesla's financial results could be limited in the short term. The company faces several challenges. He repeatedly points out that in the preliminary period until mid-2025, there are significant obstacles in increasing Cybertruck production and achieving positive cash flow . This extended time frame raises concerns about Tesla's near-term profitability. [1]

22/12/2023

Adobe grows despite botched $20 billion merger

Adobe's ambitious plan to acquire Figma for $20 billion, a move that was supposed to reshape the creative software landscape, fell through. It has been stalled by significant regulatory hurdles. The failed acquisition, announced back in September 2022, represented Adobe's strategy to expand its online creative offerings and take advantage of Figma's fast-growing market.

17/12/2023

Coca Cola dominates the market and reminds us of Christmas

Coca-Cola products have become a staple in homes all year round. But at Christmas, Coke products are particularly visible thanks to a clever advertising campaign that links the figure of Santa to the iconic brand. Yet incredibly, some 33 billion packs of the brand's products were sold in more than 200 countries last year.

10/12/2023

AstraZeneca joins the race for weight loss drug

More than one billion people worldwide are overweight or obese. AstraZeneca (AZN.L) has bet on the booming market for obesity drugs by announcing a $2 billion investment to license an experimental drug from Chinese company Eccogene.

Latest analyses